J. Kaufman

A. Nademanee, J. Dipersio, J. Kaufman, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low‐grade B‐cell lymphomas

C. Flowers, S. Lonial, J. Kaufman, 2012, Cancer.

Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma

C. Flowers, S. Lonial, J. Kaufman, 2008, Bone Marrow Transplantation.

Bortezomib‐containing induction regimens in transplant‐eligible myeloma patients

C. Flowers, S. Lonial, M. Behera, 2013, Cancer.

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

A. Jakubowiak, Wan-Jen Hong, Shaji K. Kumar, 2018, Blood advances.

The Importance of Complete Response in Outcomes in Myeloma

S. Lonial, J. Kaufman, A. Nooka, 2009, Cancer Journal.

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

M. Dimopoulos, P. Moreau, J. Kaufman, 2020, Leukemia.

Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma

S. Lonial, J. Laubach, P. Richardson, 2016, Expert opinion on biological therapy.

Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma

C. Flowers, S. Lonial, J. Kaufman, 2015, Leukemia & lymphoma.

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

Nisha S Joseph, M. Dimopoulos, S. Lonial, 2020, Blood Cancer Journal.

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial

Michael L. Wang, P. Richardson, N. Raje, 2018, JAMA oncology.

Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites

S. Lonial, Zhengjia Chen, J. Kaufman, 2018, Cancer.

Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.

S. Lonial, J. Kaufman, A. Nooka, 2017, Blood.

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

M. Amiot, R. Vij, B. Pégourié, 2017, Blood.

Perifosine Synergistically Enhances TRAIL-Induced Myeloma Cell Apoptosis via Up-Regulation of Death Receptors

S. Lonial, Shi-Yong Sun, J. Kaufman, 2008, Clinical Cancer Research.

Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents

Nisha S Joseph, C. Hofmeister, S. Lonial, 2018, Cancer.

Roundtable: How I treat a newly diagnosed patient with high-risk myeloma.

J. Kaufman, 2019, Hematology. American Society of Hematology. Education Program.

High‐risk Multiple Myeloma: Definition and Management

Nisha S Joseph, S. Lonial, J. Kaufman, 2017, Clinical lymphoma, myeloma & leukemia.

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.

C. Hofmeister, A. Jakubowiak, T. Zimmerman, 2016, Blood.

Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study

M. Amiot, R. Vij, B. Pégourié, 2016 .

Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

Jing Chen, Taro Hitosugi, Jianxin Xie, 2009, Science Signaling.

Daratumumab Plus CyBorD for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA.

M. Maurer, J. Kaufman, E. Kastritis, 2020, Blood.

Payer Perspective ASH 2011 Update: Multiple Myeloma Treatment Trends and Strategies for Value-Based Care

J. Kaufman, 2012 .

Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma

S. Lonial, J. Kaufman, A. Nooka, 2010, Cancer.

Bortezomib, Thalidomide, and Dexamethasone as Induction Therapy for Patients with Symptomatic Multiple Myeloma.

S. Lonial, J. Kaufman, C. Gleason, 2007 .

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients

S. Jagannath, S. Lonial, J. Kaufman, 2008, Leukemia.

Benefits of autologous stem cell transplant for elderly myeloma patients in the last quarter of life.

C. Hofmeister, S. Lonial, J. Kaufman, 2021, Transplantation and cellular therapy.

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

Nisha S Joseph, C. Hofmeister, S. Lonial, 2019, Blood Cancer Journal.

A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma

C. Flowers, S. Lonial, J. Kaufman, 2015, British journal of haematology.

The Tao of myeloma.

S. Lonial, J. Kaufman, L. Boise, 2014, Blood.

Multiple myeloma presenting with advanced renal failure: a case report and new treatment options.

S. Lonial, J. Kaufman, S. P. Gladney, 2008, Clinical lymphoma & myeloma.

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

Joseph D Tariman, S. Lonial, N. Munshi, 2007, Blood.

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.

E. Giné, M. Czuczman, B. Coiffier, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy

S. Jagannath, D. Siegel, F. Petrocca, 2018, Blood.

Plerixafor in combination with granulocyte–colony‐stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial

C. Flowers, S. Lonial, J. Kaufman, 2015, Transfusion.

Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.

C. Flowers, S. Lonial, J. Kaufman, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Maintenance therapy in lymphoma.

C. Flowers, S. Lonial, J. Kaufman, 2007, Clinical lymphoma & myeloma.

150: A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration

C. Flowers, S. Lonial, C. Torre, 2007 .

A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma.

C. Flowers, S. Lonial, C. Torre, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)

T. Plesner, P. Moreau, J. Kaufman, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 study of venetoclax plus car ﬁ lzomib and dexamethasone in patients with relapsed/refractory multiple myeloma

A. Jakubowiak, Wan-Jen Hong, Shaji K. Kumar, 2021 .

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.

S. Jagannath, S. Lonial, N. Munshi, 2022, The New England journal of medicine.

Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients

S. Lonial, Zhengjia Chen, J. Kaufman, 2015, Cancer.

Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?

D. Auclair, D. Siegel, J. Kaufman, 2018, Blood.

Natural history of multiple myeloma patients refractory to venetoclax: A single center experience

Nisha S Joseph, C. Hofmeister, S. Lonial, 2020, American journal of hematology.

Effectiveness and cost analysis of “just‐in‐time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics

C. Flowers, S. Lonial, J. Kaufman, 2011, Transfusion.

Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes

S. Lonial, J. Kaufman, E. Waller, 2011, Leukemia.

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study

Sharmila Patel, J. Laubach, P. Richardson, 2022, British journal of haematology.

Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN.

A. Jakubowiak, J. Laubach, P. Richardson, 2020, Blood.

Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma.

T. Plesner, H. Nahi, A. Oriol, 2019, Blood.

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

J. Fay, A. Krishnan, S. Lonial, 2017, Blood.

Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma.

S. Lonial, R. Ahmed, J. Kaufman, 2018, Journal of oncology practice.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

patients with newly diagnosed multiple myeloma Lenalidomide, bortezomib, and dexamethasone combination therapy in

D. Esseltine, S. Jagannath, A. Jakubowiak, 2012 .

Clinical Cancer esearch cer Therapy : Clinical hase I / II Trial Combining High-Dose Melphalan and ologous Transplant with Bortezomib for Multiple Myeloma : R ose-and Schedule-Finding Study

C. Flowers, C. Torre, J. Kaufman, 2010 .

BLCTT_A_245191 11..24

J. Kaufman, L. Boise, James C. Ackley, 2021 .

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

S. Lonial, J. Kaufman, A. Nooka, 2014, Leukemia.

Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.

S. Jagannath, S. Lonial, R. Vij, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

S. Jagannath, D. Siegel, R. Vij, 2010 .

Novel Approaches for the Management of AL Amyloidosis

J. Kaufman, Nisha S. Joseph, 2018, Current Hematologic Malignancy Reports.

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.

A. Krishnan, S. Lonial, J. Miguel, 2022, The Lancet. Haematology.

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma

J. Fay, B. Tunquist, J. Kaufman, 2021, Cancer medicine.

A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia

A. Jakubowiak, D. Siegel, R. Vij, 2019, Clinical Cancer Research.

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients

S. Lonial, J. Kaufman, A. Nooka, 2019, Cancer.

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

H. Goldschmidt, M. Dimopoulos, S. Jagannath, 2016, Clinical lymphoma, myeloma & leukemia.

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

M. Dimopoulos, P. Moreau, J. Kaufman, 2019, Blood.

University of Southern Denmark Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma

Clemens, Donk, T. Plesner, 2021 .

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)

T. Plesner, H. Nahi, A. Oriol, 2020, Haematologica.

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.

H. Goldschmidt, M. Dimopoulos, S. Lonial, 2022, The Lancet. Haematology.

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

S. Jagannath, R. Vij, J. Kaufman, 2015, Clinical lymphoma, myeloma & leukemia.

Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN

A. Jakubowiak, J. Laubach, P. Richardson, 2019, Clinical Lymphoma Myeloma and Leukemia.

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

A. Jakubowiak, R. Vij, A. Belch, 2009 .

Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma

C. Flowers, S. Lonial, J. Kaufman, 2018, Blood.

Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells

C. Flowers, S. Lonial, J. Kaufman, 2013 .

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

T. Plesner, H. Nahi, A. Oriol, 2017 .

Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.

Melissa L. Kemp, C. Hofmeister, S. Lonial, 2019, JCI insight.

Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy

Melissa L. Kemp, C. Hofmeister, S. Lonial, 2019 .

Daratumumab in multiple myeloma

C. Hofmeister, S. Lonial, M. Dhodapkar, 2019, Cancer.

Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.

G. Morgan, S. Lonial, N. Munshi, 2019, Clinical lymphoma, myeloma & leukemia.

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.

David D. Smith, R. Orlowski, J. Kaufman, 2015, Blood.

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

R. Vij, B. Pégourié, Shaji K. Kumar, 2017 .

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax

S. Lonial, J. Kaufman, A. Nooka, 2015, Leukemia.

A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma

B. Tunquist, S. Lonial, R. Orlowski, 2017, Cancer.

BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma

J. Kaufman, L. Boise, James C. Ackley, 2021, Blood and lymphatic cancer : targets and therapy.

Impact of concurrent gabapentin or pregabalin with high‐dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant

C. Hofmeister, S. Lonial, J. Kaufman, 2022, Pharmacotherapy.

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth

S. Lonial, Jiusheng Deng, J. Kaufman, 2016, Oncotarget.

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma

Shaji K. Kumar, P. Moreau, J. Kaufman, 2020, American journal of hematology.

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

Neeraj Gupta, Eileen Liao, Parameswaran Hari, 2014, The Lancet. Oncology.

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

A. Jakubowiak, J. Laubach, P. Richardson, 2020 .

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.

C. Hofmeister, S. Lonial, M. Dhodapkar, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis

S. Lonial, M. Behera, J. Kaufman, 2011 .

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma

C. Hofmeister, S. Lonial, M. Dhodapkar, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2010, Blood.

Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis

David D. Smith, M. Liedtke, J. Kaufman, 2015 .

Safety and survival outcomes for bloodless transplantation in patients with myeloma

C. Flowers, S. Lonial, J. Kaufman, 2018, Cancer.

Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: res

C. Flowers, S. Lonial, C. Torre, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux

S. Iida, M. Guckert, A. Oriol, 2016 .

Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors

C. Flowers, S. Lonial, J. Kaufman, 2014, Bone Marrow Transplantation.

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin

A. Jakubowiak, Sharmila Patel, J. Laubach, 2021, Blood.

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

A. Jakubowiak, Sharmila Patel, J. Laubach, 2021, Blood.

Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.

C. Flowers, S. Lonial, J. Kaufman, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma

J. Vose, C. Flowers, S. Lonial, 2013, Transfusion.

Optimizing stem cell collection through CXCR4 antagonists.

J. Kaufman, H. Mahaseth, 2012, Frontiers in bioscience.

Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience

C. Hofmeister, S. Lonial, M. Dhodapkar, 2023, Blood Cancer Journal.

IFN-α Sensitizes Human Umbilical Vein Endothelial Cells to Apoptosis Induced by Double-Stranded RNA1

J. Kaufman, M. Offermann, W. Kaiser, 2004, The Journal of Immunology.

Characteristics and outcomes of diffuse large B‐cell lymphoma presenting in leukaemic phase

D. Weisenburger, J. Armitage, M. Bast, 2012, British journal of haematology.

Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.

C. Hofmeister, S. Lonial, M. Dhodapkar, 2021, Blood cancer discovery.

Aberrant extrafollicular B cells, immune dysfunction, myeloid inflammation and MyD88-mutant progenitors precede malignancy in Waldenstrom macroglobulinemia

C. Hofmeister, S. Lonial, M. Dhodapkar, 2021 .

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

D. Auclair, J. Keats, C. Hofmeister, 2019, Nature Communications.

Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case report.

J. Kaufman, N. Wilson, R. Harvey, 2013, Clinical lymphoma, myeloma & leukemia.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

M. Dimopoulos, S. Iida, A. Belch, 2018, Haematologica.

Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma

David D. Smith, R. Orlowski, J. Kaufman, 2013 .

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

J. Keats, C. Hofmeister, S. Lonial, 2021, Blood.

Phase I, multicentre, dose‐escalation trial of monotherapy with milatuzumab (humanized anti‐CD74 monoclonal antibody) in relapsed or refractory multiple myeloma

A. Chanan-Khan, J. Kaufman, D. Goldenberg, 2013, British journal of haematology.

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

R. Vij, P. Hari, S. Iida, 2020 .

Proteasome Inhibition: Novel Therapy for Multiple Myeloma

S. Lonial, J. Kaufman, 2006, Oncology Research and Treatment.

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

C. Hofmeister, S. Lonial, B. Barwick, 2020, Blood Cancer Journal.

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

S. Jagannath, D. Siegel, N. Munshi, 2019, Blood.

Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)

Michael L. Wang, S. Lonial, N. Raje, 2014 .

Updated survival with extended follow-up on patients with newly diagnosed multiple myeloma treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy and a risk-stratified maintenance approach.

C. Hofmeister, S. Lonial, M. Dhodapkar, 2022, Journal of Clinical Oncology.

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

A. Jakubowiak, D. Siegel, J. Kaufman, 2020 .

Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, D. Siegel, 2021, Blood.

Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy.

S. Lonial, P. Richardson, J. Kaufman, 2013, Clinical lymphoma, myeloma & leukemia.

Changing Epidemiology and Improved Survival In Patients With Waldenstrom Macroglobulinemia: Review Of Surveillance, Epidemiology, and End Results (SEER) Data

S. Lonial, J. Kaufman, A. Nooka, 2013 .

Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM)

D. Siegel, S. Treon, N. Raje, 2014 .

Multiple myeloma: the role of transplant and novel treatment strategies.

S. Lonial, J. Kaufman, 2004, Seminars in oncology.

E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.

S. Lonial, M. Dhodapkar, Robert A Emmons, 2019, Journal of Clinical Oncology.

Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.

S. Lonial, J. Laubach, P. Richardson, 2020, Clinical lymphoma, myeloma & leukemia.

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

S. Lonial, J. Laubach, P. Richardson, 2019, Leukemia.

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

A. Jakubowiak, S. Lonial, J. Kaufman, 2019, Blood Cancer Journal.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carﬁlzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study

Mourad Tighiouart, Christopher R Flowers, R Donald Harvey, 2010, Clinical Cancer Research.

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.

A. Jakubowiak, Sharmila Patel, J. Laubach, 2022, Transplantation and cellular therapy.

Registering a CD38 antibody upfront for multiple myeloma

C. Hofmeister, S. Lonial, J. Kaufman, 2019, The Lancet.

Novel treatment approaches for patients with multiple myeloma.

S. Lonial, J. Kaufman, R. Sinha, 2006, Clinical lymphoma & myeloma.

Maintenance therapy in multiple myeloma

S. Lonial, J. Kaufman, R. Mihelic, 2007, Leukemia.

Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.

M. Dimopoulos, J. Miguel, S. Iida, 2019, Journal of Clinical Oncology.

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

T. Plesner, H. Nahi, A. Oriol, 2016 .

The era of combination therapy in myeloma.

S. Lonial, J. Kaufman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiple Myeloma - a New Era of Treatment Strategies

G. Tonon, S. Lonial, D. Ribatti, 2012 .

Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

S. Jagannath, A. Jakubowiak, D. Siegel, 2014 .

Retrotransposons facilitate the tissue-specific horizontal transfer of circulating tumor DNA between human cells

I. Lossos, S. Lonial, B. Vardarajan, 2022, bioRxiv.

Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study

K. Suryanarayan, J. Kaufman, S. Holstein, 2021, Blood.

TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma

K. Suryanarayan, J. Kaufman, S. Holstein, 2020 .

Putting the E (evidence) in a new Era for myeloma

S. Lonial, J. Kaufman, 2011, Leukemia & lymphoma.

A randomized clinical trial comparing granulocyte–colony‐stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation

C. Flowers, S. Lonial, J. Kaufman, 2011, Transfusion.

Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.

S. Lonial, Jiangxia Liu, J. Kaufman, 2011, Blood.

Colesevelam Hydrochloride for the Treatment of Lenalidomide Induced Diarrhea

S. Lonial, J. Kaufman, A. Nooka, 2014 .

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

M. Dimopoulos, R. Vij, P. Hari, 2020, Leukemia.

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

S. Jagannath, A. Jakubowiak, D. Siegel, 2020 .

Treatment of relapsed and refractory myeloma

S. Lonial, J. Kaufman, C. Gleason, 2009, Current hematologic malignancy reports.

Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

R. Orlowski, J. Kaufman, A. Pahl, 2022, Blood.

S181: MODAKAFUSP ALFA (TAK-573): UPDATED CLINICAL, PHARMACOKINETIC (PK), AND IMMUNOGENICITY RESULTS FROM A PHASE 1/2 STUDY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

K. Suryanarayan, J. Kaufman, D. Benson, 2022, HemaSphere.

Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

F. Gao, C. Hofmeister, R. Vij, 2022, Leukemia.

Using Serum Free Light Chain (SFLC) Ratio and Serum Protein Electrophoresis (SPEP) As a Substitute For 24-Hour Urine Studies In Myeloma Patients

S. Lonial, J. Kaufman, A. Nooka, 2013 .

Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors

C. Flowers, V. Master, J. Arora, 2017, Bone Marrow Transplantation.

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

A. Jakubowiak, S. Lonial, J. Kaufman, 2019, Blood Cancer Journal.

Venetoclax ex vivo functional profiling predicts improved progression-free survival

C. Hofmeister, S. Lonial, M. Dhodapkar, 2022, Blood Cancer Journal.

Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low α-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study

R. Orlowski, J. Kaufman, A. Nooka, 2013 .

Depth of Response and MRD with Daratumumab Plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: POLLUX

M. Dimopoulos, S. Iida, A. Belch, 2017 .

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

J. Keats, S. Lonial, A. Tron, 2018, Blood.

IFN-alpha sensitizes human umbilical vein endothelial cells to apoptosis induced by double-stranded RNA.

J. Kaufman, M. Offermann, W. Kaiser, 2004, Journal of immunology.

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

J. Burke, J. Leonard, A. Krishnan, 2019, Blood.

FDA-approved novel agents to treat relapsed and refractory myeloma

S. Lonial, J. Kaufman, C. Gleason, 2009 .

Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody

J. Blankenship, J. Kaufman, E. Ocio, 2023, Leukemia.

Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study

S. Jagannath, S. Lonial, R. Vij, 2010 .

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

F. Gao, C. Hofmeister, R. Vij, 2019, Blood.

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

S. Lonial, R. Vij, Zhengjia Chen, 2018, Blood.

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma

M. Dhodapkar, K. Leung, J. Kaufman, 2023, Journal for ImmunoTherapy of Cancer.

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

S. Jagannath, A. Jakubowiak, R. Vij, 2009 .

The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study

S. Lonial, R. Orlowski, J. Kaufman, 2012 .

Final Analysis: Phase II Study of Oral Panobinostat In Relapsed/Refractory Hodgkin Lymphoma Patients Following Autologous Hematopoietic Stem Cell Transplant

J. Kaufman, A. Younes, A. Engert, 2010 .

P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN

A. Jakubowiak, J. Laubach, P. Richardson, 2022, HemaSphere.

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2011 .

The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs),

C. Flowers, S. Lonial, M. Behera, 2011 .

Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients

C. Hofmeister, S. Lonial, M. Dhodapkar, 2018, Blood.

Phase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

M. Amiot, R. Vij, Shaji K. Kumar, 2015 .

Evaluation and Comparison of Characteristics and Outcomes Among Frontline Multiple Myeloma (FLMM) Patients with and without Stem Cell Transplant Treatment

J. Kaufman, A. Chari, M. Mehra, 2018, Blood.

Deep and Durable Responses with Weekly Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Follow-up of Patients Not Undergoing Stem Cell Transplantation (SCT)

S. Lonial, J. Laubach, P. Richardson, 2017 .

Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies

A. Jakubowiak, D. Siegel, R. Vij, 2016 .

New Treatment Strategies Making an Impact in Multiple Myeloma

J. Kaufman, C. Gleason, 2017, Journal of the advanced practitioner in oncology.

Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.

S. Jagannath, S. Lonial, R. Vij, 2009 .

First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma

D. Siegel, A. Chanan-Khan, J. Kaufman, 2008 .

A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma.

S. Lonial, S. Trudel, J. Kaufman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction

C. Hofmeister, S. Lonial, J. Kaufman, 2022, Blood.

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

A. Jakubowiak, Sharmila Patel, P. Richardson, 2022, Blood Cancer Journal.

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

A. Jakubowiak, J. Laubach, P. Richardson, 2019, Blood.

Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

A. Jakubowiak, Sharmila Patel, J. Laubach, 2021, Blood.

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

M. Dimopoulos, S. Iida, A. Oriol, 2020, Blood Cancer Journal.

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

S. Jagannath, R. Vij, J. Kaufman, 2014 .

Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma

S. Lonial, J. Kaufman, A. Nooka, 2014 .

Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

Linda Z Sun, H. Goldschmidt, M. Dimopoulos, 2011 .

Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

S. Lonial, T. Zimmerman, J. Kaufman, 2014 .

Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM).

S. Lonial, R. Orlowski, J. Kaufman, 2010 .

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

A. Hui, S. Lonial, J. Laubach, 2014 .

Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma

C. Hofmeister, S. Lonial, M. Dhodapkar, 2018, Blood.

Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma

R. Vij, J. Kaufman, F. Davies, 2018, Blood.

A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

A. Jakubowiak, P. Hari, F. Galimi, 2018, Blood.

Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial

C. Hofmeister, R. Vij, J. Kaufman, 2018, Blood.

Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma

S. Lonial, J. Kaufman, A. Nooka, 2013, Cancer biology & therapy.

Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.

A. Jakubowiak, Sharmila Patel, J. Laubach, 2022, Journal of Clinical Oncology.

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

J. Fay, A. Krishnan, S. Lonial, 2017, Blood.

Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)

A. Jakubowiak, T. Zimmerman, P. Richardson, 2008 .

Clinical Profile Of Single-Agent Modified-Release Oprozomib Tablets In Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

D. Siegel, R. Vij, J. Kaufman, 2013 .

Dermato-neuro syndrome in a patient treated with autologous stem cell transplant for scleromyxedema.

C. Flowers, J. Kaufman, D. Goldstein, 2014, Clinical lymphoma, myeloma & leukemia.

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

S. Lonial, R. Orlowski, J. Kaufman, 2011 .

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

D. Auclair, J. Keats, C. Hofmeister, 2019, Nature Communications.

Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).

M. Amiot, R. Vij, Shaji K. Kumar, 2015 .

A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency.

C. Hofmeister, S. Lonial, M. Dhodapkar, 2023, Journal of Clinical Oncology.

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy

C. Hofmeister, S. Lonial, M. Dhodapkar, 2023, The Journal of clinical investigation.

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

S. Iida, A. Oriol, P. Moreau, 2017 .

Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).

M. Dimopoulos, R. Vij, T. Zimmerman, 2016 .

Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)

S. Lonial, J. Kaufman, A. Nooka, 2017 .

Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies

S. Lonial, Zhengjia Chen, J. Kaufman, 2019, Cancer.

A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results.

A. Jakubowiak, T. Zimmerman, P. Richardson, 2007 .

Blood and Lymphatic Cancer: Targets and Therapy

J. Kaufman, L. Boise, M. Petrucci, 2021 .

Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.

Melissa L. Kemp, C. Hofmeister, S. Lonial, 2019, JCI insight.

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.

S. Lonial, Shi-Yong Sun, J. Kaufman, 2011, Blood.

Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States

D. Auclair, D. Siegel, J. Kaufman, 2022, Patient preference and adherence.

PPA_A_345906 573..585

D. Auclair, D. Siegel, J. Kaufman, 2022 .

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

Multiple myeloma immunoglobulin λ translocations portend poor prognosis

D. Auclair, J. Keats, S. Lonial, 2018, bioRxiv.

A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma

C. Flowers, S. Lonial, J. Kaufman, 2015, British journal of haematology.

Impaired SARS-CoV-2 variant neutralization and CD8+ T cell responses following 3 doses of mRNA vaccines in myeloma: correlation with breakthrough infections.

A. Sette, C. Hofmeister, S. Lonial, 2022, Blood cancer discovery.

A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis

David D. Smith, M. Liedtke, J. Kaufman, 2014 .

Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.

M. Amiot, R. Vij, B. Pégourié, 2016 .

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

A. Jakubowiak, Sharmila Patel, J. Laubach, 2022, Blood.

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.

A. Jakubowiak, Sharmila Patel, J. Laubach, 2023, The Lancet. Haematology.

The research mission in myeloma

S. Jagannath, A. Jakubowiak, N. Munshi, 2009, Leukemia.

Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)

A. Jakubowiak, T. Zimmerman, P. Richardson, 2010 .

A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma

M. Dimopoulos, R. Vij, T. Zimmerman, 2015 .